Page last updated: 2024-11-08

lunularin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

lunularin: first source misnames compound; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID181511
CHEMBL ID445252
CHEBI ID6568
SCHEMBL ID717118
MeSH IDM0338136

Synonyms (25)

Synonym
37116-80-6
lunularin
3,4'-ethylenebisphenol
LMPK13090039
3-[2-(4-hydroxyphenyl)ethyl]phenol
chebi:6568 ,
CHEMBL445252
unii-axg9ep247c
axg9ep247c ,
3,4'-(ethane-1,2-diyl)diphenol
3,4'-dihydroxybibenzyl
SCHEMBL717118
phenol, 3-[2-(4-hydroxyphenyl)ethyl]-
1-(4-hydroxyphenyl)-2-(3-hydroxyphenyl)ethane
DTXSID20190614
AKOS027461006
3-(4-hydroxyphenethyl)phenol
FT-0731060
DS-19179
mfcd24713452
Q6704488
C74915
CS-0086842
lunularine
3-(2-(4-hydroxyphenyl)ethyl)phenol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
stilbenoidAny olefinic compound characterised by a 1,2-diphenylethylene backbone.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID1296790Antimicrobial activity against 2-phenoxyphenol/methicillin-resistant Staphylococcus aureus after 18 to 20 hrs by liquid microdilution method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Minimum structural requirements for cell membrane leakage-mediated anti-MRSA activity of macrocyclic bis(bibenzyl)s.
AID396592Antileishmanial activity against Leishmania amazonensis IFLA/BR/67/PH8 promastigotes assessed as lysis of promastigotes at 100 ug/ml after 72 hrs2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies.
AID717875Antibacterial activity against methicillin-resistant Staphylococcus aureus OM584 by two-fold liquid microdilution method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Riccardin C derivatives as anti-MRSA agents: structure-activity relationship of a series of hydroxylated bis(bibenzyl)s.
AID1625243Cytotoxic activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2019Journal of natural products, 04-26, Volume: 82, Issue:4
Cytotoxic Activity of Riccardin and Perrottetin Derivatives from the Liverwort Lunularia cruciata.
AID1202489Cytotoxicity against mouse J774 cells assessed as cell viability after 48 hrs by resazurin assay2015European journal of medicinal chemistry, , Volume: 96Bond-based bilinear indices for computational discovery of novel trypanosomicidal drug-like compounds through virtual screening.
AID396591Antileishmanial activity against Leishmania braziliensis MHOM/BR/75/M2903 promastigotes assessed as lysis of promastigotes at 100 ug/ml after 72 hrs2008European journal of medicinal chemistry, Sep, Volume: 43, Issue:9
Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies.
AID1625245Cytotoxic activity against human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by MTT assay2019Journal of natural products, 04-26, Volume: 82, Issue:4
Cytotoxic Activity of Riccardin and Perrottetin Derivatives from the Liverwort Lunularia cruciata.
AID1296789Antimicrobial activity against methicillin-resistant Staphylococcus aureus OM481 clinical isolate after 18 to 20 hrs by liquid microdilution method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Minimum structural requirements for cell membrane leakage-mediated anti-MRSA activity of macrocyclic bis(bibenzyl)s.
AID1202488Trypanosomicidal activity against epimastigote stage of Trypanosoma cruzi CL-B5 after 72 hrs by beta-galactosidase reporter gene assay2015European journal of medicinal chemistry, , Volume: 96Bond-based bilinear indices for computational discovery of novel trypanosomicidal drug-like compounds through virtual screening.
AID1296788Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315 after 18 to 20 hrs by liquid microdilution method2016Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
Minimum structural requirements for cell membrane leakage-mediated anti-MRSA activity of macrocyclic bis(bibenzyl)s.
AID1202490Selectivity ratio of IC50 for mouse J774 cells to IC50 for epimastigote stage of Trypanosoma cruzi CL-B52015European journal of medicinal chemistry, , Volume: 96Bond-based bilinear indices for computational discovery of novel trypanosomicidal drug-like compounds through virtual screening.
AID717874Antibacterial activity against methicillin-resistant Staphylococcus aureus OM481 by two-fold liquid microdilution method2012Bioorganic & medicinal chemistry letters, Dec-15, Volume: 22, Issue:24
Riccardin C derivatives as anti-MRSA agents: structure-activity relationship of a series of hydroxylated bis(bibenzyl)s.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (7.14)18.2507
2000's2 (14.29)29.6817
2010's7 (50.00)24.3611
2020's4 (28.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.36 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.55 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.14%)5.53%
Reviews1 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (85.71%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]